Role of VEGF and CD44v6 in differentiating benign from malignant ascites
Open Access
- 1 January 2003
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 9 (11) , 2596-2600
- https://doi.org/10.3748/wjg.v9.i11.2596
Abstract
Role of VEGF and CD44v6 in differentiating benign from malignant ascitesKeywords
This publication has 44 references indexed in Scilit:
- Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long‐term prognosisJournal of Surgical Oncology, 2002
- Gonadotropin Stimulation of MLS Human Epithelial Ovarian Carcinoma Cells Augments Cell Adhesion Mediated by CD44 and by αv-IntegrinGynecologic Oncology, 2002
- Malignant ascitesAmerican Journal of Hospice and Palliative Medicine®, 2002
- Soluble CD44 Isoforms in Serum as Potential Markers of Metastatic Gastric CarcinomaJournal of Clinical Gastroenterology, 1996
- CD44 splice variants: metastases meet lymphocytesImmunology Today, 1993
- The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNABiochemical and Biophysical Research Communications, 1991
- A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cellsCell, 1991
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.Journal of Clinical Investigation, 1989
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989